• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    President & CEO Blum Robert I was granted 11,530 shares and covered exercise/tax liability with 2,935 shares, increasing direct ownership by 2% to 399,604 units (SEC Form 4)

    12/29/25 4:09:03 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYTK alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Blum Robert I

    (Last) (First) (Middle)
    350 OYSTER POINT BLVD

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CYTOKINETICS INC [ CYTK ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President & CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    12/22/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/22/2025 A(1) 5,765 A $0 396,774 D
    Common Stock 12/22/2025 A(2) 5,765 A $0 402,539 D
    Common Stock 12/22/2025 F(3) 2,935 D $62.72 399,604 D
    Common Stock 2,083 I by Trust 1(4)
    Common Stock 2,083 I by Trust 2(5)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Performance shares earned as a result of achieving performance goal. Shares remain subject to 1-year time vesting requirement.
    2. Performance Stock Units earned upon achieving performance goal. Shares have been vested.
    3. Withholding of shares for tax on performance shares that have been earned and vested.
    4. Shares held by The Bridget Blum 2003 Irrevocable Trust.
    5. Shares held by The Brittany Blum 2003 Irrevocable Trust.
    /s/ John O. Faurescu, attorney-in-fact for Mr. Blum 12/24/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CYTK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYTK

    DatePrice TargetRatingAnalyst
    1/28/2026$87.00Overweight
    Barclays
    12/18/2025$95.00Neutral → Buy
    Goldman
    7/30/2025Mkt Perform
    Raymond James
    4/24/2025$55.00Overweight
    Barclays
    2/7/2025$86.00Buy
    Citigroup
    1/22/2025$80.00Buy
    Stifel
    11/8/2024$80.00Outperform
    RBC Capital Mkts
    8/13/2024$85.00 → $60.00Buy → Neutral
    Goldman
    More analyst ratings

    $CYTK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

    MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that MYQORZO™ (aficamten) is now available for prescription in 5 mg, 10 mg, 15 mg and 20 mg tablets in the U.S. MYQORZO was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. Experience the full interactive Multichannel News Release here: https://www.multivu.com/cytokinetics/9379451-en-myqorzo-now-avai

    1/27/26 7:30:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that on January 15, 2026 it granted stock options to purchase an aggregate of 29,416 shares of common stock and 19,825 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 8 employees, whose employment commenced in December 2025 and January 2026 as a material inducement to their employment. The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniver

    1/20/26 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    SEC Filings

    View All

    Cytokinetics Incorporated filed SEC Form 8-K: Other Events

    8-K - CYTOKINETICS INC (0001061983) (Filer)

    12/19/25 4:01:36 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Incorporated filed SEC Form 8-K: Other Events

    8-K - CYTOKINETICS INC (0001061983) (Filer)

    12/12/25 8:54:21 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Incorporated filed SEC Form 8-K: Leadership Update

    8-K - CYTOKINETICS INC (0001061983) (Filer)

    11/14/25 4:05:27 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Daly James M was granted 197 shares (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    1/20/26 4:17:27 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wysenski Nancy was granted 98 shares, increasing direct ownership by 0.32% to 30,971 units (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    1/16/26 4:22:27 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Wierenga Wendell was granted 98 shares, increasing direct ownership by 0.30% to 32,542 units (SEC Form 4)

    4 - CYTOKINETICS INC (0001061983) (Issuer)

    1/16/26 4:20:42 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays resumed coverage on Cytokinetics with a new price target

    Barclays resumed coverage of Cytokinetics with a rating of Overweight and set a new price target of $87.00

    1/28/26 7:16:37 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics upgraded by Goldman with a new price target

    Goldman upgraded Cytokinetics from Neutral to Buy and set a new price target of $95.00

    12/18/25 8:41:18 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James resumed coverage on Cytokinetics

    Raymond James resumed coverage of Cytokinetics with a rating of Mkt Perform

    7/30/25 7:32:47 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Leadership Updates

    Live Leadership Updates

    View All

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

    "On Track with HCM" Features Practical Insights for Managing Everyday Life with the Disease, Inspired by the Experience with HCM of McLaughlin-Levrone's Father, Willie McLaughlin SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the launch of "On Track with HCM," demonstrating the company's long-standing commitment to the HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy (HCM) for more than two decades before receiving a heart trans

    1/27/26 8:00:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Names Jim Daly to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with particular expertise in commercialization to the Company's Board of Directors. "Jim has longstanding expertise leading commercial launches of innovative therapies, coupled with extensive Board experience guiding later-stage, global biopharma companies," said Robert I. Blum, Cytokinetics' President and Chief Executive Officer. "We are pleased to welcome him to our Board and look forward to his contributi

    8/20/25 7:30:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Names Robert E. Landry to Board of Directors

    Appointment Deepens Financial and Operational Expertise of Boardas Company Approaches Potential Commercialization SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in the pharmaceutical industry, most recently having served as the Chief Financial Officer at Regeneron Pharmaceuticals Inc. for 11 years. "We are pleased to have Bob join our Board as we approach a key shareholder value inflection point for the company and prepare for the potential approval and launch of our first medici

    2/11/25 7:30:00 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Cytokinetics Incorporated

    SC 13G - CYTOKINETICS INC (0001061983) (Subject)

    11/14/24 1:28:31 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

    SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)

    11/12/24 2:21:36 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cytokinetics Incorporated

    SC 13G/A - CYTOKINETICS INC (0001061983) (Subject)

    11/12/24 9:55:17 AM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYTK
    Financials

    Live finance-specific insights

    View All

    Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

    MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company's First FDA-Approved Medicine Company to Host Investor Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. MYQORZO is an allosteric and rever

    12/19/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

    Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track Ex-U.S. Regulatory Reviews of Aficamten Ongoing in China and E.U. ~$1.25 Billion in Cash, Cash Equivalents and Investments as of September 30, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) reported a management update and financial results for the third quarter of 2025. "I'm pleased that our teams continue to demonstrate strong execution and sustained momentum as we approach the PDUFA date for the aficamten NDA. Our commercial preparations have been deliberate and strategic, positioning us well

    11/5/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cytokinetics to Announce Third Quarter Results on November 5, 2025

    SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that it is scheduled to report third quarter results on November 5, 2025 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics' website at www.cytokinetics.com or directly at the following link: Cytokinetics Q3 2025 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics' w

    10/22/25 4:00:00 PM ET
    $CYTK
    Biotechnology: Pharmaceutical Preparations
    Health Care